Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial-Reference-Cited by-同舟云学术

Amantadine for COVID-19 treatment (ACT) study: a randomized, double-blinded, placebo-controlled clinical trial

Published:2023-10 Issue:10 Volume:29 Page:1313-1319
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Weis Nina,Bollerup Signe,Sund Jon Dissing,Glamann Jakob Borg,Vinten Caroline,Jensen Louise Riger,Sejling Christoffer,Kledal Thomas Nitschke,Rosenkilde Mette Marie

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. Amantadine: the journey from fighting flu to treating Parkinson disease;Hubsher;Neurology,2012

2. The emerging influenza virus threat: status and new prospects for its therapy and control;Kumar;Arch Virol,2018

3. Effect of pre-exposure use of amantadine on COVID-19 infection: a hospital-based cohort study in patients with Parkinson's disease or multiple sclerosis;Kamel;Front Neurol,2021

4. Amantadine for COVID-19;Grieb;J Clin Pharmacol,2021

5. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment;Rejdak;Mult Scler Relat Disord,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing the field of viroporins—Structure, function and pharmacology: IUPHAR Review 39;British Journal of Pharmacology;2024-09-03

2. Ultrasensitive SERS aptasensor using Au@Ag bimetallic nanorod SERS tags for the selective detection of amantadine in foods;Food Chemistry;2024-09

3. Amantadine in unvaccinated patients with early, mild to moderate COVID‐19: A randomized, placebo‐controlled, double‐blind trial;European Journal of Neurology;2023-09-14